MFIM
IMDX

Mesirow Financial Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Mesirow Financial Investment Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,964
Closed -$190K – 76
2020
Q2 		$190K Sell
4,964
-8
-0.2% -$413 0.89% 67
2020
Q1 		$244K Sell
4,972
-3,129
-39% -$153K 1.54% 32
2019
Q4 		$365K Sell
8,101
-313
-4% -$11.3K 1.54% 33
2019
Q3 		$353K Buy
+8,414
New +$331K 1.48% 42

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Mesirow Financial Investment Management's IMDX Position: Q3 2020 in Review

Mesirow Financial Investment Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2020, closing a stake of 4,964 shares — an estimated $190K sold.

Mesirow Financial Investment Management first reported a position in IMDX in Q3 2019 and held it in 4 quarters. The position peaked at $365K in Q4 2019. 59 funds tracked by Wall St. Rank hold IMDX as of Q3 2020.

  • Mesirow Financial Investment Management reported no remaining Insight Molecular Diagnostics position as of Q3 2020 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 4,964 Insight Molecular Diagnostics shares in Q3 2020, an estimated $190K.
  • Mesirow Financial Investment Management first reported a position in Insight Molecular Diagnostics in Q3 2019 and held it in 4 quarters.
  • Mesirow Financial Investment Management's Insight Molecular Diagnostics position peaked at $365K in Q4 2019.
  • 59 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2020.

Based on Mesirow Financial Investment Management's 13F filing for Q3 2020, filed 13 Oct 2020.